Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives $81.50 Average PT from Analysts

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) have earned an average rating of “Moderate Buy” from the thirteen research firms that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and eleven have issued a buy recommendation on the company. The average 1 year price target among brokers that have covered the stock in the last year is $81.50.

RARE has been the subject of a number of analyst reports. Canaccord Genuity Group cut their price objective on shares of Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a “buy” rating for the company in a research report on Friday, August 8th. Morgan Stanley lowered their target price on shares of Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an “overweight” rating for the company in a research note on Monday, July 14th. Wells Fargo & Company reduced their price target on Ultragenyx Pharmaceutical from $88.00 to $65.00 and set an “overweight” rating on the stock in a research note on Thursday, July 10th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $105.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Friday, September 5th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, October 8th.

Ultragenyx Pharmaceutical Stock Up 1.8%

NASDAQ RARE opened at $32.02 on Friday. Ultragenyx Pharmaceutical has a fifty-two week low of $25.81 and a fifty-two week high of $57.99. The business has a fifty day moving average of $29.82 and a 200-day moving average of $32.94. The stock has a market cap of $3.09 billion, a price-to-earnings ratio of -5.79 and a beta of 0.21.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) EPS for the quarter, beating analysts’ consensus estimates of ($1.27) by $0.10. Ultragenyx Pharmaceutical had a negative return on equity of 237.48% and a negative net margin of 87.34%.The business had revenue of $166.50 million for the quarter, compared to analyst estimates of $161.37 million. During the same quarter last year, the company earned ($1.52) earnings per share. The business’s revenue for the quarter was up 13.2% compared to the same quarter last year. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. As a group, analysts anticipate that Ultragenyx Pharmaceutical will post -5.18 EPS for the current year.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In related news, EVP Karah Herdman Parschauer sold 2,450 shares of the firm’s stock in a transaction that occurred on Friday, September 12th. The shares were sold at an average price of $31.17, for a total value of $76,366.50. Following the sale, the executive vice president directly owned 73,271 shares of the company’s stock, valued at approximately $2,283,857.07. This trade represents a 3.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 5.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

Large investors have recently bought and sold shares of the stock. Price T Rowe Associates Inc. MD grew its stake in shares of Ultragenyx Pharmaceutical by 28.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,218,942 shares of the biopharmaceutical company’s stock valued at $116,559,000 after buying an additional 706,519 shares during the period. Adage Capital Partners GP L.L.C. boosted its holdings in Ultragenyx Pharmaceutical by 81.6% in the first quarter. Adage Capital Partners GP L.L.C. now owns 2,149,000 shares of the biopharmaceutical company’s stock valued at $77,815,000 after acquiring an additional 965,919 shares during the last quarter. Federated Hermes Inc. grew its position in Ultragenyx Pharmaceutical by 0.3% during the first quarter. Federated Hermes Inc. now owns 2,055,200 shares of the biopharmaceutical company’s stock valued at $74,419,000 after acquiring an additional 5,400 shares during the period. Geode Capital Management LLC increased its stake in Ultragenyx Pharmaceutical by 4.0% during the second quarter. Geode Capital Management LLC now owns 1,712,931 shares of the biopharmaceutical company’s stock worth $62,291,000 after acquiring an additional 66,394 shares during the last quarter. Finally, Deutsche Bank AG raised its holdings in shares of Ultragenyx Pharmaceutical by 0.5% in the 1st quarter. Deutsche Bank AG now owns 1,701,493 shares of the biopharmaceutical company’s stock worth $61,611,000 after purchasing an additional 8,385 shares during the period. Hedge funds and other institutional investors own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.